This is a preview of subscription content, access via your institution
Relevant articles
Open Access articles citing this article.
-
Questions concerning tyrosine kinase-inhibitor therapy and transplants in chronic phase chronic myeloid leukaemia
Leukemia Open Access 25 March 2022
Access options
Subscribe to this journal
Receive 12 print issues and online access
$259.00 per year
only $21.58 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
References
Clift RA, Buckner CD, Thomas ED, Doney K, Fefer A, Neiman PE et al. Treatment of chronic granulocytic leukaemia in chronic phase by allogeneic marrow transplantation. Lancet 1982; 2: 621–623.
Baccarani M, Deininger MW, Rosti G, Hochhaus A, Soverini S, Apperley JF et al. European LeukemiaNet recommendations for the management of chronic myeloid leukemia. Blood 2013; 122: 872–884.
Barrett AJ, Ito S . The role of stem cell transplantation for chronic myelogenous leukemia in the 21st century. Blood 2015; 125: 3230–3235.
Saussele S, Lauseker M, Gratwohl A, Beelen DW, Bunjes D, Schwerdtfeger R et al. Allogeneic hematopoietic stem cell transplantation (allo SCT) for chronic myeloid leukemia in the imatinib era: evaluation of its impact within a subgroup of the randomized German CML Study IV. Blood 2010; 115: 1880–1885.
Warlick E, Ahn KW, Pedersen TL, Artz A, de Lima M, Pulsipher M et al. Reduced intensity conditioning is superior to nonmyeloablative conditioning for older chronic myelogenous leukemia patients undergoing hematopoietic cell transplant during the tyrosine kinase inhibitor era. Blood 2012; 119: 4083–4090.
Pavlu J, Szydlo RM, Goldman JM, Apperley JF . Three decades of transplantation for chronic myeloid leukemia: what have we learned? Blood 2011; 117: 755–763.
Gratwohl A, Hermans J, Goldman JM, Arcese W, Carreras E, Devergie A et al. Risk assessment for patients with chronic myeloid leukaemia before allogeneic blood or marrow transplantation. Chronic Leukemia Working Party of the European Group for Blood and Marrow Transplantation. Lancet 1998; 352: 1087–1092.
Gray RJ . A Class of K-Sample Tests for Comparing the Cumulative Incidence of a Competing Risk. Ann Stat 1988; 16: 1141–1154.
Gratwohl A, Brand R, Apperley J, Crawley C, Ruutu T, Corradini P et al. Allogeneic hematopoietic stem cell transplantation for chronic myeloid leukemia in Europe 2006: transplant activity, long-term data and current results. Haematologica 2006; 91: 513–521.
Acknowledgements
The cooperation of all participating teams and their staff (listed after the Reference section) and the Chronic Malignancies Working Party Registry (AvB) is greatly appreciated.
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Competing interests
The authors declare no conflict of interest.
Appendix
Appendix
List of participating teams:
M Rovira20, P Kahls21, A Alegre22, D Nemet23, D Stamatovic24, A Vitek25, R Hamladji26, A Hellmann27, A Chybicka28, W Wiktor-Jedrzejczak29, A Maiolino30, P von dem Borne31, P Chevallier32, T Littlewood33, C Crawley34, M Mistrik35, K Schäfer-Eckart36, K Orchard37, J Maertens38, M van Lint39, M Ethell40, K Vettenranta41, A Broom42, E Deconinck43, N Schaap44, E Petersen45, CR Espiga46, P Di Bartolomeo47, P Brown48, D Beelen49, V Leblond50, X Leleu51, K Carlson52, N Milpied53, M Collin54, J Johansson55, R Cairoli56, H Serwe57, M Schleuning58, M Ozturk59, IA Lisukov60, S Robinson61, D Uckan-Cetinkaya62, P Rohrlich63, G Visani64, F Merli65, M Sanz66, M Michallet67, K Halaburda68, T O’Brien69, P Jindra70, L Feldman71, M Theobald72, C Favre73, F Rodeghiero74, J Finke75
20Hospital Clinic, Barcelona, Spain, 21Medizinische Universitaet Wien, Vienna, Austria, 22Hospital de la Princesa, Madrid, Spain, 23University Hospital Center – Rebro, Zagreb, Croatia, 24Military Medical Academy, Belgrade, Serbia and Montenegro, 25Inst. of Hematology and Blood Transf., Prague, Czech Republic, 26Centre Pierre et Marie Curie, Alger, Algeria, 27Medical University of Gdansk, Gdansk, Poland, 28Wroclaw Medical University, Wroclaw, Poland, 29The Medical University of Warsaw, Warsaw, Poland, 30Univ. Fed. do Rio de Janeiro, Rio de Janeiro Ilha do Fundão, Brazil, 31Leiden University Hospital, Leiden, The Netherlands, 32Hotel Dieu, Nantes, France, 33The Oxford Radcliffe Hospital, Oxford, UK, 34Addenbrookes Hospital, Cambridge, UK, 35Univ. Hosp. Clinic of Hemat. & Transfusiology, Bratislava, Slovakia, 36Klinikum Nürnberg, Nürnberg, Germany, 37Southampton General Hospital, Southampton, UK, 38University Hospital of Leuven, Leuven, Belgium, 39Ospedale San Martino, Genova, Italy, 40Royal Marsden Hospital, Sutton, UK, 41University of Helsinki, Helsinki, Finland, 42Western General Hospital, Edinburgh, Scotland, UK, 43Hopital Jean Minjoz, Besancon, France, 44Univ. Med. Cent. St Radboud, Nijmegen, The Netherlands, 45University Medical Centre Utrecht, Utrecht, The Netherlands, 46Hospital Univ. ‘Marqués de Valdecilla’, Santander, Spain, 47Ospedale Civile, Pescara, Italy, 48St James Hospital Trinity College, Dublin, Ireland, 49University Hospital, Essen, Germany, 50Pitie-Salpetriere, Paris, France, 51Hopital La Miletrie, Poitiers, France, 52University Hospital, Uppsala, Sweden, 53Hopital Haut-Leveque, Pessac, France, 54Royal Victoria Infirmary, Newcastle-upon-Tyne, UK, 55Sahlgrenska University Hospital, Goeteborg, Sweden, 56Ospedale di Niguarda Ca’Granda, Milano, Italy, 57Universität Frankfurt, Frankfurt, Germany, 58Deutsche Klinik für Diagnostik, Wiesbaden, Germany, 59Gulhane Military Medical Academy, Ankara, Turkey, 60Institute of Clinical Immunology, Novosibirsk, Russia, 61Bristol Royal Hospital for Children, Bristol, UK, 62Hacettepe University Childrens Hospital, Ankara, Turkey, 63Hôpital de l’Arget, Nice, France, 64Pesaro Hospital, Pesaro, Italy, 65Arcispedale S Maria Nuova Unita Oper. Emat., Reggio Emilia, Italy, 66Hospital Universitario La Fe,Valencia, Spain, 67Hopital E Herriot, Lyon, France, 68Institute of Haematology and Blood Transfusion, Warsaw, Poland, 69Sydney Children’s Hospital, Randwick, NSW, Australia, 70Charles University Hospital, Pilsen, Czech Republic, 71Antartida Hospital Privado, Buenos Aires, Argentina, 72University Medical Center Mainz, Mainz, Germany, 73Unità Operativa Oncoematologia Pediatrica, Pisa, Italy, 74S Bortolo Hospital, Vicenza, Italy, 75University Hospital Freiburg, Freiburg, Germany.
Rights and permissions
About this article
Cite this article
Koenecke, C., Heim, D., van Biezen, A. et al. Outcome of patients with chronic myeloid leukemia and a low-risk score: allogeneic hematopoietic stem cell transplantation in the era of targeted therapy. A report from the EBMT Chronic Malignancies Working Party. Bone Marrow Transplant 51, 1259–1261 (2016). https://doi.org/10.1038/bmt.2016.97
Published:
Issue Date:
DOI: https://doi.org/10.1038/bmt.2016.97